Search

Author/Creator Lawitz, Eric

11. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients. (6th December 2015)

Authors:
Everson, Gregory T.; Sims, Karen D.; Thuluvath, Paul J.; Lawitz, Eric; Hassanein, Tarek; Rodriguez‐Torres, Maribel; Desta, Tadesse; Hawkins, Trevor; Levin, James M.; Hinestrosa, Federico; Rustgi, Vinod; Schwartz, Howard; Younossi, Zobair; Webster, Lynn; Gitlin, Norman; Eley, Timothy; Huang, Shu‐P...
Journal:
Liver international
Issue:
Volume 36:Number 2(2016)
Page Start:
189
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Development of sofosbuvir for the treatment of hepatitis C virus infection. Issue 1 (31st July 2015)

Authors:
Lawitz, Eric; Jacobson, Ira M.; Nelson, David R.; Zeuzem, Stefan; Sulkowski, Mark S.; Esteban, Rafael; Brainard, Diana; McNally, John; Symonds, William T.; McHutchison, John G.; Dieterich, Douglas; Gane, Edward
Journal:
Annals of the New York Academy of Sciences
Issue:
Volume 1358:Issue 1(2015)
Page Start:
56
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Issue 6 (16th November 2022)

Authors:
Feld, Jordan J; Lawitz, Eric; Nguyen, Tuan; Lalezari, Jacob; Hassanein, Tarek; Martin, Paul; Han, Steven-Huy; Dieterich, Douglas; Giard, Jeanne-Marie; De La Rosa, Guy; Ahmad, Alaa; Luo, Ed; Conery, Annie L; Adda, Nathalie
Journal:
Antiviral therapy
Issue:
Volume 27:Issue 6(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015)

Authors:
Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y M;...
Journal:
Lancet
Issue:
Volume 385:Issue 9973(2015)
Page Start:
1075
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015)

Authors:
Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y M;...
Journal:
Lancet
Issue:
Volume 385:Issue 9973(2015)
Page Start:
1075
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Issue 9 (11th July 2019)

Authors:
Lawitz, Eric; Gane, Edward; Feld, Jordan J.; Buti, Maria; Foster, Graham R.; Rabinovitz, Mordechai; Burnevich, Eduard; Katchman, Helena; Tomasiewicz, Krzysztof; Lahser, Fred; Jackson, Beth; Shaughnessy, Melissa; Klopfer, Stephanie; Yeh, Wendy W.; Robertson, Michael N.; Hanna, George J.; Barr, Eli...
Other Names:
Gordon Stuart C. investigator.; Lawitz Eric J. investigator.; Ruane Peter Jerome investigator.; Sahota Amandeep investigator.; Terrault Norah A. investigator.; Tsai Naoky investigator.; Kalathil Sumodh C. investigator.; Reddy Gautham investigator.; Ghesquiere Wayne investigator.; Borgia Sergio in...
Journal:
Journal of viral hepatitis
Issue:
Volume 26:Issue 9(2019)
Page Start:
1127
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. (26th December 2019)

Authors:
Lawitz, Eric; Flisiak, Robert; Abunimeh, Manal; Sise, Meghan E.; Park, Jun Y.; Kaskas, Marwan; Bruchfeld, Annette; Wörns, Marcus‐Alexander; Aglitti, Andrea; Zamor, Philippe J.; Xue, Zhenyi; Schnell, Gretja; Jalundhwala, Yash J.; Porcalla, Ariel; Mensa, Federico J.; Persico, Marcello
Journal:
Liver international
Issue:
Volume 40:Number 5(2020)
Page Start:
1032
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Issue 6 (12th March 2019)

Authors:
Lawitz, Eric; Poordad, Fred; Anderson, Leah J.; Vesay, Michelle; Kelly, Michelle M.; Liu, Hong; Gao, Wei; Fernsler, Doreen; Asante‐Appiah, Ernest; Robertson, Michael N.; Hanna, George J.; Barr, Eliav; Butterton, Joan; Kowdley, Kris V.; Hassanein, Tarek; Sahota, Amandeep; Gordon, Stuart C.; Yeh, W...
Journal:
Journal of viral hepatitis
Issue:
Volume 26:Issue 6(2019)
Page Start:
675
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. Fibroscan Is a Feasible and Useful Point‐Of‐Care Tool to Assess Nonalcoholic Fatty Liver Disease Severity in Children Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX: 1015. (October 2019)

Authors:
Cummings‐John, Oladuni D.; Geistweidt, Stephenie; Okubote, Toluwalase C.; Ascher Bartlett, Johanna M.; Filo, Jean; Betancourt, Amanda; Alkhouri, Naim; Lawitz, Eric; Angueira, Candice
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor. Issue 7 (October 2014)

Authors:
Nelson, David; Yoshida, Eric M; Paulson, Matthew S; Hengen, Paul N; Ge, Dongliang; Kanwar, Bittoo; McNally, John; Pang, Phillip S; Subramanian, G Mani; McHutchison, John G; Urbanek, Petr; Lawitz, Eric; Urban, Thomas J
Journal:
Antiviral therapy
Issue:
Volume 19:Issue 7(2014)
Page Start:
679
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗